Edesa Biotech, Inc. 8-K

What Happened
Edesa Biotech, Inc. (EDSA) announced on February 24, 2026 that additional Phase 3 results for its anti‑TLR4 antibody paridiprubart met the study’s primary endpoint in the full 278‑patient safety population. In the randomized (1:1) trial (paridiprubart n=138; placebo n=140), adjusted 28‑day mortality was 24% with paridiprubart versus 33% with placebo — a 27% relative risk reduction (p<0.001). The benefit was consistent across severity groups, including previously reported invasive mechanical ventilation (IMV) patients and a non‑IMV subgroup, and overall safety and adverse event rates were similar between groups.

Key Details

• Study size and timing: Full safety population n=278 (reported Feb 24, 2026); IMV ITT prespecified subset n=104; non‑IMV exploratory subgroup n=174.
• Primary endpoint: Adjusted 28‑day mortality — 24% paridiprubart vs. 33% placebo (27% relative reduction; p<0.001).
• Non‑IMV subgroup: 15% vs. 23% (35% relative reduction; p<0.005, nominal). IMV ITT: 39% vs. 52% (p<0.001).
• Secondary endpoint: ≥2‑point improvement in WHO COVID‑19 Severity Scale by Day 28 — 52% paridiprubart vs. 45% placebo (p<0.01).
• Exploratory comorbidity results (nominal p<0.05): pneumonia (n=108) 35% vs. 49%; acute kidney injury (n=48) 35% vs. 53%; sepsis (n=41) 40% vs. 63%.
• Safety & exposure: Adverse events, serious AEs, infections and discontinuations were low and similar between arms; >400 patients have now received paridiprubart.
• IP & funding: Provisional U.S. patent applications filed for sepsis, AKI and pneumonia uses; core patents extend into the 2030s. Paridiprubart development and scale‑up also receive U.S. and Canadian government funding. Ongoing separate U.S. government‑funded ARDS study enrolling up to ~200 randomized subjects.

Why It Matters
For investors, the filing signals that Edesa’s lead asset achieved its predefined primary endpoint in a Phase 3 population with statistically significant mortality reduction and a generally consistent safety profile—key facts that can affect regulatory plans, partnering interest, and valuation discussions. The company also strengthened intellectual property coverage and is pursuing additional government‑funded studies, but note the filing’s forward‑looking caution: these are clinical results and further regulatory review, confirmatory data and other milestones are still required before commercialization.